Oramed Pharmaceuticals Inc has announced that randomization of patients in its first Phase 3 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D) is under way.
The study by the clinical-stage pharmaceutical company focused on the development of oral drug delivery, is being conducted in accordance with U.S. Food and Drug Administration (FDA) approved protocols.
Oramed CEO Nadav Kidron said, “We’re excited to be the first company in the world to conduct an FDA approved Phase 3 study for oral insulin.”
Kidron added: “This is an important study and we’re pleased that recruitment for the study is proceeding as planned. We look forward to sharing more updates as we progress.”
Glucose-lowering agents
ORA-D-013-1 is roping in 675 patients who are currently on two or three oral glucose-lowering agents through 75 clinical sites throughout the U.S.
The study’s primary endpoint is to compare the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by A1c, with a secondary endpoint of assessing the change from baseline in fasting plasma glucose at 26 weeks. Efficacy data will become available after all patients have completed the first 6-month treatment period.
The trial is a double blind, double dummy study randomizing patients 1:1:1 for: 8 mg ORMD-0801 once-daily at night and placebo 45 minutes before breakfast; or 8 mg ORMD-0801 twice-daily at night and 45 minutes before breakfast; or placebo twice-daily at night and 45 minutes before breakfast.
(With inputs from The OnLook News Research Bureau)
![](https://theonlook.com/wp-content/uploads/2023/10/For-wordpress.jpg")
If you like this article and if you feel it will be helpful for others to understand on the subject, please share it. You can also follow us on Twitter, Facebook & Linkedin
Also read: Keep your heart healthy with these easy tips from Harvard medical school
